Nat Prod Sci.  2018 Jun;24(2):88-92. 10.20307/nps.2018.24.2.88.

Garcinexanthone G, a Selective Butyrylcholinesterase Inhibitor from the Stem Bark of Garcinia atroviridis

Affiliations
  • 1Discipline of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia.
  • 2School of Chemical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia.
  • 3School of Distance Education, Universiti Sains Malaysia, 11800 Penang, Malaysia. tanwn@usm.my

Abstract

The present study was undertaken to investigate the isolated compounds from the stem bark of Garcinia atroviridis as potential cholinesterase inhibitors and the ligand-enzyme interactions of selected bioactive compounds in silico. The in vitro cholinesterase results showed that quercetin (3) was the most active AChE inhibitor (12.65 ± 1.57 µg/ml) while garcinexanthone G (6) was the most active BChE inhibitor (18.86 ± 2.41 µg/ml). It is noteworthy to note that compound 6 was a selective inhibitor with the selectivity index of 11.82. Molecular insight from docking interaction further substantiate that orientation of compound 6 in the catalytic site which enhanced its binding affinity as compared to other xanthones. The nature of protein-ligand interactions of compound 6 is mainly hydrogen bonding, and the hydroxyl group of compound 6 at C-10 is vital in BChE inhibition activity. Therefore, compound 6 is a notable lead for further drug design and development of BChE selective inhibitor.

Keyword

Garcinia atroviridis; Garcinexanthone G; Butyrylcholinesterase; Molecular docking

MeSH Terms

Butyrylcholinesterase*
Catalytic Domain
Cholinesterase Inhibitors
Cholinesterases
Computer Simulation
Drug Design
Garcinia*
Hydrogen Bonding
In Vitro Techniques
Quercetin
Xanthones
Butyrylcholinesterase
Cholinesterase Inhibitors
Cholinesterases
Quercetin
Xanthones

Figure

  • Fig. 1. The structures of compounds 1 – 6 from the stem bark of G. atroviridis.

  • Fig. 2. Binding interactions of compounds 4 – 6 and galanthamine with the amino acids of butyrylcholinesterase. A-D represents compounds 4 – 6 and galanthamine, respectively.


Reference

References

(1). Tarawneh R.., Holtzman D. M.Cold Spring Harb. Perspect. Med. 2012. 2:, a006148.
(2). Prince M.., Comas-Herrera A.., Knapp M.., Guerchet M.., Karagiannidou M.World Alzheimer Report. 2016.
(3). Herrup K.Nat. Neurosci. 2015. 18:794–799.
(4). Aguzzi A.., O'Connor T.Nat. Rev. Drug Discov. 2010. 9:237–248.
(5). Hardy J.., Selkoe D. J.Science. 2002. 297:353–356.
(6). Colovi M. B.., Krsti D. Z.., Lazarevi -Pašti T. D.., Bondži A. có có có có M.., Vasi V. M.Curr. Neuropharmacol. 2013. 11:315–335.
(7). Scarpini E.., Schelterns P.., Feldman H.Lancet Neurol. 2003. 2:539–547.
(8). Darvesh S.., Grantham D. L.., Hopkins D. A. J.Comp. Neurol. 1998. 393:374–390.
(9). Perry E. K.., Perry R. H.., Blessed G.., Tomlinson B. E.Neuropathol. Appl. Neurobiol. 1978. 4:273–277.
(10). Quinn D. M.Chem. Rev. 1987. 87:955–979.
Article
(11). Sussman J. L.., Harel M.., Frolow F.., Oefner C.., Goldman A.., Toker L.., Silman I.Science. 1991. 253:872–879.
(12). Greig N. H.., Utsuki T.., Ingram D. K.., Wang Y.., Pepeu G.., Scali C.., Yu Q. S.., Mamczarz J.., Holloway H. W.., Giordano T.., Chen D.., Furukawa K.., Sambamurti K.., Brossi A.., Lahiri D. K. Proc. Natl. Acad. Sci. U. S.A. 2005. 102:17213–17218.
(13). Tan W. N.., Khairuddean M.., Wong K. C.., Khaw K. Y.., Vikneswaran M.Fitoterapia. 2014. 97:261–267.
(14). Tan W. N.., Khairuddean M.., Wong K. C.., Tong W. Y.., Ibrahim D. J.Asian Nat. Prod. Res. 2016. 18:804–811.
(15). Ellman G. L.., Courtney K. D.., Andres V. Jr.., Feather-Stone R. M.Biochem. Pharmacol. 1961. 7:88–95.
(16). Morris G. M.., Goodsell D. S.., Halliday R. S.., Huey R.., Hart W. E.., Belew R. K.., Olson A. J. J.Comput. Chem. 1998. 19:1639–1662.
(17). Carletti E.., Aurbek N.., Gillon E.., Loiodice M.., Nicolet Y.., Fontecilla-Camps J. -C.., Masson P.., Thiermann H.., Nachon F.., Worek F.Biochem. J. 2009. 421:97–106.
(18). Humphrey W.., Dalke A.., Schulten K. J.Mol. Graph. 1996. 14:33–38.
(19). Khaw K. Y.., Choi S. B.., Tan S. C.., Wahab H. A.., Chan K. L.., Murugaiyah V.Phytomedicine. 2014. 21:1303–1309.
(20). Louh G. N.., Lannang A. M.., Mbazoa C. D.., Tangmouo J. G.., Komguem J.., Castilho P.., Ngninzeko F. N.., Qamar N.., Lontsi D.., Choudhary M. I.., Sondengam B. L.Phytochemistry. 2008. 69:1013–1017.
(21). Khan M. T. H.., Orhan I.., Senol F. S.., Kartal M.., Sener B.., Dvorská M.., Smejkal K.., Slapetová T.Chem. Biol. Interact. 2009. 181:383–389.
(22). Sriraksa N.., Wattanathorn J.., Muchimapura S.., Tiamkao S.., Brown K.., Chaisiwamongkol K.Evid. Based Complement. Alternat. Med. 2012. 2012:823206.
Full Text Links
  • NPS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr